Drugs / Molidustat
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02312973 | Jan → Dec 2015 | chronic kidney disease | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01679587 | Sep 2012 → Feb 2013 | kidney disorder | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01458028 | Sep → Dec 2011 | anemia | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01332942 | Apr 2011 → May 2013 | anemia | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01318551 | Mar 2011 → Sep 2013 | anemia | Bayer | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT02055482 | Jun 2014 → Nov 2016 | anemia, chronic kidney disease | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT02064426 | Mar 2014 → Oct 2016 | anemia, chronic kidney disease | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT02021370 | Feb 2014 → Sep 2015 | anemia, chronic kidney disease | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT02021409 | Jan 2014 → Oct 2015 | anemia, chronic kidney disease | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT01975818 | Oct 2013 → Oct 2015 | anemia, chronic kidney disease | Bayer | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT03543657 | Jun 2018 → Aug 2019 | anemia, chronic kidney disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT03418168 | Feb 2018 → Jul 2019 | anemia, chronic kidney disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT03351166 | Jan → Oct 2018 | anemia, chronic kidney disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT03350347 | Dec 2017 → Jul 2019 | anemia, chronic kidney disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT03350321 | Dec 2017 → May 2019 | anemia, chronic kidney disease | Bayer | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Molidustat | “Subjects received an oral single dose of 5 mg of molidustat IR tablet on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).” NCT01332942 ↗ |
| Known as | BAY 1053048 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3646118 ↗ |
| Known as | BAY-85-3934 SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL3646118 ↗ |
| Known as | BAY85-3934 | “Investigation of Pharmacokinetics, Safety, Tolerability, and Pharmacodynamic Effects of BAY85-3934 in Male and Female Subjects With Renal Impairment and in Age- and...” NCT01318551 ↗15“Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets” NCT02021409 ↗ “Molidustat (BAY 85-3934)” NCT01975818 ↗ “Molidustat (BAY85-3934)” NCT03351166 ↗ “Molidustat (BAY85-3934)” NCT03543657 ↗ “Molidustat (BAY85-3934)” NCT03418168 ↗ “Molidustat (BAY85-3934)” NCT02055482 ↗ “Molidustat (BAY85-3934)” NCT02064426 ↗ “Molidustat (BAY85-3934)” NCT03350321 ↗ “Molidustat (BAY85-3934)” NCT01679587 ↗ “Molidustat (BAY85-3934)” NCT03350347 ↗ |
| Known as | MOLIDUSTAT SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL3646118 ↗ |
| Action | Inhibit | “Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor” CHEMBL3646118 ↗3“Molidustat is an oral HIF-PH inhibitor” PMID 31203242 ↗ Jun 2019 “Egl nine homolog 1 inhibitor” CHEMBL3646118 ↗ “Egl nine homolog 3 inhibitor” CHEMBL3646118 ↗ |
| Modality | Small molecule | — CHEMBL3646118 ↗ |
| Route | Oral | “single oral dose” NCT01318551 ↗ |
| Target | EGLN1 | “Egl nine homolog 1 inhibitor” CHEMBL3646118 ↗ |
| Target | EGLN2 | “Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor” CHEMBL3646118 ↗ |
| Target | EGLN3 | “Egl nine homolog 3 inhibitor” CHEMBL3646118 ↗ |